Abstract
Introduction
Rheumatoid arthritis (RA) composite disease activity indices have become handy tools in daily clinical practice and crucial in defining remission or low disease activity, the main target of the RA treatment. However, there is no definition of the best index to assess disease activity in clinical practice.
Objectives
To compare the residual activity among the indices with the ACR/EULAR remission criteria (Boolean method) to identify the most feasible for assessing remission in daily practice, also considering correlation and concordance, sensibility, and specificity.
Patients and methods
We selected 1116 patients with established RA from the real-life rheumatoid arthritis study database—REAL. The composite disease activity indices—DAS28-ESR, DAS28-CRP, SDAI, and CDAI–and their components were compared to the Boolean method to identify residual activity using binomial regression. The indices were analyzed for correlation and agreement using the Spearman index and weighted kappa. The chi-square test evaluated sensibility and specificity for remission based on the Boolean method.
Results
DAS28-CRP overestimated remission and confirmed higher residual activity than SDAI and CDAI. The indices showed good correlation and agreement, with a better relationship between SDAI and CDAI (k:0,88). CDAI and SDAI showed higher sensitivity and specificity for remission based on the Boolean method. CDAI was performed in 99% of patients, while DAS28 and SDAI were completed in approximately 85%.
Conclusions
Although all composite indices of activity can be used in clinical practice and showed good agreement, CDAI and SDAI have better performance in evaluating remission based on the Boolean method, showing less residual activity and higher sensibility and specificity. In addition, CDAI seems to be more feasible for disease activity evaluation in daily clinical practice, especially in developing countries.
Funder
Brazilian Society of Rheumatology
Bristol-Myers Squibb
Bristol-Myers Squibb Farmaceutica Ltda
Eli Lilly do Brasil Ltda
Janssen Cilag Farmacêuticos Ltda
Laboratorios Pfizer Ltda
Produtos Roche Quimicos e Farmacêuticos Ltda
UCB Biopharma Ltda
Publisher
Public Library of Science (PLoS)
Reference48 articles.
1. Rheumatoid arthritis;JS Smolen;Lancet,2016
2. Rheumatoid arthritis;JS Smolen;Nat Rev Dis Prim,2018
3. Multicentric study of the prevalence of adult rheumatoid arthritis in Brazilian population samples;JF Marques-Neto;Rev Bras Reum,1993
4. The global burden of rheumatoid arthritis: Estimates from the Global Burden of Disease 2010 study;M Cross;Ann Rheum Dis,2014
5. Long-term outcomes of treat-to-target strategy in established rheumatoid arthritis: a daily practice prospective cohort study;NPB de Andrade;Rheumatol Int,2017
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献